RA Session II, Taysha Gene Therapies CEO
October 25, 2022 06:56 AM EDTUpdated October 26, 12:16 PM
Deals
Cell/Gene Tx

Pre­lude to buy­out? Astel­las picks up Taysha stock, two gene ther­a­py pro­grams for $50M

Amber Tong

Half a year af­ter Taysha Gene Ther­a­pies laid off 35% of its staffers and paused the bulk of its R&D work, the Dal­las crew has …

Endpoints News

Sign up to read this article for free.

Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.

BECOME A PREMIUM SUBSCRIBER
TRENDING NOW

The End­points 2024 win­ners and losers list: Who was up and who was down in bio­phar­ma

Up­dat­ed: No­vo’s 23% weight loss with Ca­griSe­ma falls short of high ex­pec­ta­tions, new tri­al planned

FDA ap­proves Hu­ma­cyte’s lab-grown blood ves­sels in mile­stone for re­gen­er­a­tive med­i­cine

Ac­cel­er­at­ed ap­proval brings Pfiz­er's BRAF in­hibitor to first-line pa­tients

Califf, on his way out at FDA, pre­dicts agency tug-of-war be­tween Ra­maswamy and RFK Jr.

Ex­clu­sive: Flori­da can­cer biotech rais­es $100M Se­ries A

A service from the Financial Times